Eloxx Pharmaceuticals, Inc.
NASDAQ Capital MarketTotal Valuation
Eloxx Pharmaceuticals, Inc. carries a market capitalization of 90.88M, placing it among publicly traded companies globally. Its enterprise value stands at 3.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 90.88M |
| Enterprise Value | 3.09M |
Share Statistics
Eloxx Pharmaceuticals, Inc. currently has 278,944.00 shares outstanding.
| Shares Outstanding | 278,944.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.00 |
| P/TBV Ratio | -0.01 |
| P/FCF Ratio | -0.02 |
| P/OCF Ratio | -0.02 |
Financial Position
Eloxx Pharmaceuticals, Inc. maintains a current ratio of 0.07, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -17.55, indicating conservative leverage, while an interest coverage ratio of -14.32 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.07 |
| Quick Ratio | 0.05 |
| Debt / Equity | -17.55 |
| Debt / EBITDA | -0.24 |
| Interest Coverage | -14.32 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -149.37 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Eloxx Pharmaceuticals, Inc.'s stock has gained approximately 11999900.36% over the past 52 weeks. The 50-day moving average sits at 12.32, while the 200-day moving average is 12.32.
| Beta (5Y) | N/A |
| 52-Week Price Change | 11999900.36% |
| 50-Day Moving Average | 12.32 |
| 200-Day Moving Average | 12.32 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -16.48M, while operating income came in at -17.29M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -17.29M |
| Pretax Income | -17.05M |
| Net Income | -17.05M |
| EBITDA | -16.48M |
| EBIT | -17.29M |
| Earnings Per Share (EPS) | -78.97 |
Balance Sheet
Eloxx Pharmaceuticals, Inc. holds 1.13M in cash and equivalents against 3.97M in total debt, resulting in a net debt position of 2.70M. Total book value stands at -291.41M, with working capital of -21.15M providing operational flexibility.
| Cash & Cash Equivalents | 1.13M |
| Total Debt | 3.97M |
| Net Debt | 2.70M |
| Equity (Book Value) | -291.41M |
| Book Value Per Share | -1,349.43 |
| Working Capital | -21.15M |
Cash Flow
Eloxx Pharmaceuticals, Inc. produced -14.34M in operating cash flow over the past twelve months.
| Operating Cash Flow | -14.34M |
| Capital Expenditures | N/A |
| Free Cash Flow | -14.34M |
| FCF Per Share | -66.41 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 1,575.20 |
| FCF Yield | -5,534.05 |
Stock Splits
Eloxx Pharmaceuticals, Inc.'s most recent stock split took place on June 1, 2026 with a 11:1 split ratio.
| Last Split Date | 6/1/2026 |
| Split Ratio | 11:1 |
Scores
Eloxx Pharmaceuticals, Inc. posts an Altman Z-Score of -286.47, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -286.47 |